Devices and methods for inhibiting granulocyte activation by neural stimulation

Abstract

Described herein are methods, devices and systems for inhibition of granulocyte activation by appropriate stimulation of the vagus nerve. Methods of treating granulocyte-mediated disorders (including inflammatory disorders) by stimulating the vagus nerve to inhibit granulocyte activation (particularly neutrophil activation) are also described. Appropriate stimulation may be very low levels of stimulation, including stimulation that does not result in desensitization. The level of granulocyte activation may be detected and used to at least partially control stimulation.

Description

BACKGROUND OF THE INVENTION

Neutrophils, eosinophils and basophils are known as granulocytes because of their content of cytoplasmic granules, or phagocytes because they may phagocytize or ingest bacteria, microorganisms and other types of foreign materials. These cells are produced from common progenitor cells in the bone marrow of a human or animal, and are known to circulate in peripheral blood and enter tissues as necessary for control of infection or to participate in any type of inflammatory reaction. The neutrophil is the most common leukocyte in human and animal peripheral blood.

In the response to any type of infection or inflammation, granulocytes are activated to migrate to the appropriate area in response to chemoattractant factors, such as, certain bacterial products, complement component, and other factors. This attraction process is termed chemotaxis. Once in an area of inflammation or infection, granulocytes and mononuclear phagocytes must establish a firm attachment to their targets. For this purpose, these cells possess a number of specific cell surface receptor glycoproteins that promote this interaction, such as complement, Fc, and fibronectin receptors.

One family of cell surface receptor glycoproteins is the leukocyte cell adhesion molecular (LEU-CAM) family (CD11/CD18). This family is comprised of cell surface proteins which have multiple subunits. The members of this family include LFA-1 (CD 11a/CD18), Mol (CD 11b/CD18), and P150,94 (CD 11c/CD18).

Activation of granulocytes (and particularly neutrophils) is involved in numerous disorders and diseases, particularly those involving inflammation. While the inflammatory response of granulocytes is vital to the eradication of invading microorganisms, substantial evidence indicates that inflammatory phagocytes cause damage to various organs and tissues when these cells are activated as part of an ongoing (chronic) process, or are triggered in an unregulated manner. The adhesion and spreading of activated granulocytes (e.g., neutrophils) to vascular endothelial cells with the subsequent release of toxic oxidative metabolites and proteases has been implicated in the organ damage observed in diseases or disorders (“granulocyte-mediated disorders”) such as adult respiratory distress syndrome (ARDS; shock lung syndrome), glomerulonephritis, and inflammatory injury occurring after reperfusion of ischemic tissue such as to the heart, bowel, and central nervous system, among others. Heart muscle or myocardium may be particularly vulnerable to the inflammatory response of activated granulocytes. For example, it has been suggested that inhibition of the activation of granulocytes prior to cardiac insult (e.g., myocardial ischemia) may result in significantly smaller damage, and reduced myocardial infarct size.

U.S. Pat. No. 4,840,793 to Todd III, et al., as well as related U.S. Pat. No. 4,935,234, U.S. Pat. No. 5,049,659 and U.S. Pat. No. 5,019,648 describe the inhibition of activated granulocytes by administering monoclonal antibodies that inhibit adhesion-dependent functions of glycoproteins such as CD11b to inhibit migration of neutrophils to an area of inflammation or infection. Other groups have used recombinant soluble adhesive receptors as anti-inflammatory compounds. Thus, the majority of treatments for granulocyte-mediated disorders or diseases have been treated by systemically applying exogenous substances that interact with granulocytes that have already undergone activation. It would be highly desirable to more directly inhibit granulocyte activation, as described herein.

SUMMARY OF THE INVENTION

Described herein are methods of inhibiting granulocyte activation and devices and systems for inhibiting granulocyte activation. The methods, devices and systems described herein may inhibit granulocyte activation by appropriate stimulation of the vagus nerve. In particular, neutrophil activation may be inhibited by appropriate vagus nerve stimulation. Cellular activation of granulocytes (including neutrophils) may be detected by the expression of cell-surface receptors such as CD11b or other cellular components that are part of a cellular immunity or inflammation response associated with granulocytes.

The methods and systems described herein may be particularly useful to prevent or treat granulocyte-mediated diseases or disorders. Examples of such disorders and diseases are provided below. In general, granulocyte-mediated diseases or disorders include any disease or disorder in which activated granulocytes cause, enhance or exacerbate a deleterious biological effect, including inflammatory disorders or diseases. This includes all neutrophil-mediated diseases or disorders. For example, diabetes, atherosclerosis, and many cancers are neutrophil-mediated diseases.

In general, a granulocyte-mediated disorder may be prevented and/or treated by stimulating the vagus nerve in an appropriate manner. For example, a method of treating and/or preventing a granulocyte-mediated disease or disorder may include the steps of identifying a subject suffering from, or at risk for, a disease or disorder mediated by granulocyte activation, and stimulating the subject's vagus nerve in an amount sufficient to achieve an inhibition in expression of a marker of granulocyte activation without desensitizing the response of the granulocytes to vagal stimulation.

Appropriate stimulation of the vagus nerve results in an inhibition of granulocyte activation (particularly sustained inhibition of neutrophil activation), without desensitizing the inhibitory pathway by overstimulating the vagus nerve. For example, appropriate stimulation may be extremely low frequency, low level stimulation. Examples of appropriate stimulation are provided below. Appropriately stimulating the vagus nerve may result in a sustained inhibition in granulocyte activation, which can be detected or measured by examining the expression of a marker of granulocyte activation, such as CD11b. In some variations, the stimulation of the subject's vagus nerve results in inhibition of expression of some markers of granulocyte activation (such as cell-surface receptors like CD11b) without substantially inhibiting the expression of other granulocyte proteins. Thus, the subject's vagus nerve may be specifically stimulated to achieve a reduction of expression of a marker of granulocyte activation without substantially reducing the expression of other markers, such as HLA-DR (Ia) and other class II antigens.

The vagus nerve may be stimulated to inhibit granulocyte activation by any appropriate mode of stimulation. In particular, the vagus nerve may be stimulated by electrical stimulation, mechanical stimulation, or electromagnetic stimulation. These methods of stimulation may be direct or indirect. Indirect stimulation of the vagus nerve may be performed through tissue (e.g., transvascularly, transcutaneously, etc.). A stimulator may be external or implanted, and may be particularly configured to provide the extremely low frequency, low level stimulation described below. In some variations, the stimulator is activated or controlled by feedback from one or more sensors configured to detect activation (e.g., activation level) of granulocytes (e.g., the level or change in level of CD11b on neutrophils).

Mechanical stimulation of the vagus nerve may involve applying pressure to the vagus nerve. For example, mechanical stimulation may be applied by pressing or squeezing the nerve, or a region of tissue including a portion of the vagus nerve. Pressure may be applied externally (e.g., to a region of the body enervated by a branch of the vagus nerve such as the pinna region of the ear), or internally (e.g., from an implant).

In some variations, the method of treating and/or preventing a granulocyte-mediated disorder may include the step of implanting a stimulator for stimulating the vagus nerve. For example, a stimulator may be a transvascular stimulator that is implanted subclavically.

Treatment and/or prevention of a granulocyte-mediated disorder may also involve the step of detecting activated granulocytes, or the activation level of granulocytes. The activation level of granulocytes may be determined by detecting the expression of markers of granulocyte activation, such as the detection (and/or quantification) of a cell-surface marker such as CD11b on neutrophils. Changes in the activation level of granulocytes (such as neutrophils) may be used to control the stimulation of the vagus nerve to inhibit granulocyte activation. Thus, this information may be used to provide feedback to control or regulate stimulation of the vagus nerve to inhibit granulocyte activation. As described in further detail below, the activation level of granulocytes may also be examined to identify or characterize a subject that is a good candidate for vagal stimulation to inhibit granulocyte activation, and therefore a good candidate to receive vagal stimulation to prevent or treat a granulocyte-mediated disease or disorder.

The methods and devices for inhibiting granulocyte activation described herein may be limited to inhibition of one class of granulocytes, such as neutrophils. In some variations, the methods and devices described herein may be selective (or substantially selective) for inhibition of one class of granulocytes over another class of granulocytes. For example, activation of neutrophils may be inhibited preferentially compared to activation of eosinophils. Furthermore, activation of granulocytes or a class of granulocytes may be assayed by any appropriate marker for granulocyte activation, including cell surface receptor glycoproteins such as CD11b. In some variations, the activation of granulocytes refers to the level of surface expression of CD11b.

A granulocyte-mediated disorder or disease may refer to any granulocyte-mediated disorder or disease, particularly inflammatory diseases or disorders in which granulocyte activity has been implicated, and where inhibition of granulocyte activation (e.g., neutrophil activation) may be beneficial. Examples of granulocyte-mediated diseases or disorders include, but are not limited to: diabetes, atherosclerosis, and other inflammatory disorders. In some variations, the granulocyte-mediated disorders are neutrophil-mediated disorders or disorders in which CD11b has been implicated (“CD11b-mediated disorders).

Also described herein are methods of treating and/or preventing a granulocyte-mediated disease or disorder in a subject that include the step of stimulating the subject's vagus nerve in an amount sufficient to inhibit the expression of CD11b on the surface of the subject's granulocyte cells without desensitizing the response of the granulocytes to vagal stimulation. In some variations, the stimulation of the subject's vagus nerve is sufficient to inhibit CD11b expression for longer than an extended period time, such as greater than 12 hours, greater than 24 hours, greater than 36 hours, etc.

As mentioned, any appropriate vagal stimulation may be used, including mechanical stimulation, electrical stimulation, and/or electromagnetic stimulation. In particular, the stimulation may be extremely low frequency, low level stimulation. For example, the vagus nerve may be stimulated mechanically by a pulse of light vibration energy (e.g., between 0.1 and 400 Hz (e.g., between 0.1 Hz and 200 Hz, between 0.1 and 100 Hz, between 0.1 and 60 Hz, between 0.1 and 30 Hz, between 0.1 and 10 Hz, between 0.1 and 1 Hz, etc.), applied for between about 30 minutes and about 30 second (e.g., between about 20 minutes and about 30 seconds, between about 10 minutes and 30 seconds, between about 5 minutes and 1 minute, etc.). A pulse of stimulation may then be followed by a quiescent (unstimulated) time period of between about 2 hours and about 72 hours. For example, the quiescent time period may be approximately 12 hours, 24 hours, 36 hours, 48 hours, etc. It may be preferably to tailor the quiescent time period to the actual level of granulocyte activation. Similarly, electrical or electromagnetic stimulation may also be performed. For example, electrical stimulation may be very light (e.g., less than100 mV, less than 10 mV, less than 1 mV, etc.) at an inter-stimulus frequency of between 0.1 Hz and 200 Hz, between 0.1 and 100 Hz, between 0.1 and 60 Hz, between 0.1 and 30 Hz, between 0.1 and 10 Hz, between 0.1 and 1 Hz, etc.), applied for between about 30 minutes and about 30 second (e.g., between about 20 minutes and about 30 seconds, between about 10 minutes and 30 seconds, between about 5 minutes and 1 minute, etc.). A pulse of stimulation may then be followed by a quiescent (unstimulated) time period of between about 2 hours and about 72 hours. Any appropriate stimulation intensity, duration, inter-stimulus frequency, and quiescent period may be used. Light intensity and low-frequency stimulation is particularly useful.

As mentioned briefly above, stimulation of the vagus nerve may also be controlled or coordinated with detection of granulocyte activation. Also described herein are methods for treating and/or preventing a granulocyte-mediated disease or disorder in a subject in which granulocyte activation is measured. These methods may include the step of detecting a granulocyte activation level and applying stimulation to the subject's vagus nerve to inhibit granulocyte activation in response to the detected granulocyte activation level. These methods may use feedback to control activation of vagus nerve to inhibit granulocyte activation. For example, in some variations the method also includes detecting a second granulocyte activation level and applying a second stimulation to the subject's vagus nerve in response to the second subject's vagus level.

The step of detecting a granulocyte activation level may involve the detection of expression of CD11b expression on granulocytes. As mentioned above, stimulation may include mechanical stimulation, electrical stimulation, and/or electromagnetic stimulation.

Also described herein are systems for treating or preventing a granulocyte-mediated disease or disorder in a subject. These systems may include a sensor to detect granulocyte activation level and a stimulator for stimulating a vagus nerve in response to the detected granulocyte activation level. For example, the sensor may be configured to determine CD11b expression on granulocyte cells. The stimulator may be configured to stimulate the vagus nerve in an amount sufficient to inhibit granulocyte activation without desensitizing the response of the granulocytes to vagal stimulation.

Also described herein are systems to treat or prevent a granulocyte-mediated disease or disorder in a subject. The system may include a sensor to detect CD11b expression on neutrophils, and a stimulator for mechanically stimulating a vagus nerve in response to the level of CD11b expression, whereby the neutrophil activation is inhibited.

INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

A better understanding of the features and advantages of the present invention will be obtained by reference to the following drawings.

FIG. 1 illustrates one variation of a method of screening a subject to determine the subject's response to inhibition of granulocyte activation by vagal stimulation.

FIG. 2 is a schematic illustration of a system for stimulating the vagus nerve to inhibit granulocyte activation.

FIG. 3 illustrates one variation of a method for stimulating the vagus nerve of a subject to inhibit granulocyte activation.

FIG. 4 is a graph showing the effect of VNS on total (neutrophil) CD11b expression in one subject in the LPS unchallenged situation.

FIG. 5 is a graph showing the effect of VNS on total (neutrophil) CD11b expression in one subject in the LPS challenged situation.

FIG. 6. is a bar graph of the percent reduction in neutrophil CD11b expression (and thus granulocyte activation) in one subject following VNS in the LPS unchallenged situation, compared to immediately before stimulation.

FIG. 7 is a bar graph of the percent reduction in neutrophil CD11b expression (and thus granulocyte activation) in one subject following VNS in the LPS challenged situation, compared to immediately before stimulation.

DETAILED DESCRIPTION OF THE INVENTION

The methods, devices and systems described herein originate from the surprising observation that granulocyte activation may be inhibited by appropriate stimulation of the inflammatory reflex, which includes the vagus nerve. Thus, granulocyte-mediated disorders and diseases may be prevented, treated and/or lessened by appropriately stimulating the inflammatory reflex. This basic observation is described below, followed by a discussion and illustrations of the types of stimulation that are appropriate for inhibiting granulocyte activation. A description of some of the applications of vagal stimulation to inhibit granulocyte activation is also described, including variations of devices, systems and methods of treatment. Specific examples of inhibition of granulocyte activation are also provided. Although the examples and description refer to stimulation of the vagus nerve, it should be understood that the same effect described in the methods, devices and systems herein may be achieved by appropriate stimulation of other portions of the inflammatory reflex. The Vagus nerve is part of an inflammatory reflex, which also includes the splenic nerve, the hepatic nerve and the trigeminal nerve. The efferent arm of the inflammatory reflex may be referred to as the cholinergic anti-inflammatory pathway. For example, Tracey et. al., have previously reported that the nervous system regulates systemic inflammation through a Vagus nerve pathway. This pathway may involve the regulation of inflammatory cytokines and/or activation of granulocytes. Thus, it is believed that appropriate modulation of the Vagus nerve may help regulate inflammation.

As used herein, the term “vagus nerve” may refer to any cranial nerve X, including the main nerve, and any nerves that branch off of the main vagus nerve, as well as ganglionic or post-ganglionic neurons connected to the vagus nerve. The vagus nerve may be referred to as a cholinergic nerve, and may include both afferent and efferent nerve fibers. The term “stimulation” in reference to the vagus nerve is described in greater detail below, but may include any appropriate type of stimulation, including mechanical, electrical, electromagnetic, etc. Stimulation may be direct, e.g., via contact with a portion of the vagus nerve (e.g., by electrode) or indirect, through one or more adjacent tissues or barriers (including external stimulation from outside of the body). A patient (or subject) may include any mammal, preferably a human, but may include domestic, farm, laboratory, or wild animals.

As mentioned above, a granulocyte typically refers to a neutrophil, esinophil or basophil. In some of the variations described herein, the “granulocytes” referred to are neutrophils. In other variations, a granulocyte may refer to any of neutrophil, eosinophil, or basophil. A granulocyte may transform from an un-activated granulocyte into an activated granulocyte (e.g., an activated neutrophil). Once activated, granulocytes can migrate into tissue, and/or move to a specific body region via chemotaxis.

A granulocyte-mediated disease or disorder may include any disease or disorder in which activated granulocytes cause, enhance or exacerbate a deleterious biological effect, including inflammatory disorders or diseases. Granulocyte-mediated diseases or disorders include neutrophil-mediated diseases or disorders. Non-limiting examples of granulocyte-mediated diseases or disorders include: diabetes, atherosclerosis, many cancers, septic shock, acute respiratory distress syndrome (ARDS), bacterial meningitis, acute pancreatitis, multiple organ failure (MOF), post-ischemic reperfusion, acute cellulitis, abdominal aortic aneurysm, asthma, osteomyelitis, Crohn's disease, cystic fibrosis, emphysema, septic or bacterial pyelonephritis, rheumatoid arthritis, septic arthritis, uveitis, periodontitis, psoriasis, severe burns, skin ulceration, acute lung injury, pneumonia, trauma, severe early graft dysfunction, brochioeactasis, chronic obstructive pulmonary disease (COPD), complications with hemodialysis, hypersensitivity pneumonitis, lung fibrosis, herpes stromal keratitis, vascular restenosis, glomerulonephritis, hypersensitivity, cardiac rupture arising as a complication of myocardial infarction, multiple sclerosis, stroke and cerebral ischemia, and traumatic brain injury.

1. Basic Observation

Granulocyte activation may be inhibited by appropriate stimulation of the vagus nerve. In particular, stimulation of the vagus nerve at low intensity and low frequency may result in an inhibition of granulocyte activation following the appropriate stimulation. For example, endotoxin added to blood taken from a subject prior to stimulation of the subject's vagus nerve results in activation of granulocytes, particularly neutrophils. Endotoxin added to blood taken from a subject after external mechanical stimulation of the subject's vagus nerve (as described in Example 1, below) shows a much lower level of granulocyte activation. As described, below, the level of granulocyte activation maybe determined by the detection of CD11b on surface of granulocytes.

Furthermore, markers of granulocyte activation such as CD11b are altered by the appropriate stimulation of the vagus nerve, while other markers (such as HLA-DR) are not substantially altered by this stimulation. Although not wishing to be bound by theory, the vagal stimulation may be acting through the spleen to effect activation of granulocytes. The spleen is enervated by the vagus nerve, and typically receives approximately 20% of cardiac output per minute, including circulating granulocytes. Thus, virtually all of the circulating granulocytes pass through the spleen every five minutes. The vagus nerve may therefore signal the spleen to control activation of the granulocytes.

2. Stimulation

In general, appropriate vagus nerve stimulation that may be applied to inhibit granulocyte activation is extremely low frequency, low level stimulation. The range of appropriate stimulation parameters may depend on the particular stimulation modality (e.g., mechanical, electrical, electromagnetic, etc.) that is used, as well as the location of the stimulation (e.g., external, internal, etc.). For example, when electrically stimulating the vagus nerve to inhibit granulocyte activation, very low-intensity (e.g., less than 1V, less than 100 mV, less than 10 mV, less than 1 mV, less than 0.1 mV, less than 0.001 mV) may be used. Similarly, when mechanically stimulating the vagus nerve, a light touch or light pressure on the vagus nerve may be used. For example, the vagus nerve may be stimulated mechanically by a pulse of light vibration energy (e.g., between 0.1 and 400 Hz (e.g., between 0.1 Hz and 200 Hz, between 0.1 and 100 Hz, between 0.1 and 60 Hz, between 0.1 and 30 Hz, between 0.1 and 10 Hz, between 0.1 and 1 Hz, etc.), applied for between about 30 minutes and about 30 second (e.g., between about 20 minutes and about 30 seconds, between about 10 minutes and 30 seconds, between about 5 minutes and 1 minute, etc.). A pulse of stimulation may then be followed by a quiescent (unstimulated) time period of between about 2 hours and about 72 hours. For example, the quiescent time period may be approximately 12 hours, 24 hours, 36 hours, 48 hours, etc. It may be preferably to tailor the quiescent time period to the actual level of granulocyte activation. Similarly, electrical or electromagnetic stimulation may also be performed. For example, electrical stimulation may be very light (e.g., less than 100 mV, less than 10 mV, less than 1 mV, etc.) at an inter-stimulus frequency of between 0.1 Hz and 200 Hz, between 0.1 and 100 Hz, between 0.1 and 60 Hz, between 0.1 and 30 Hz, between 0.1 and 10 Hz, between 0.1 and 1 Hz, etc.), applied for between about 30 minutes and about 30 second (e.g., between about 20 minutes and about 30 seconds, between about 10 minutes and 30 seconds, between about 5 minutes and 1 minute, etc.). A pulse of stimulation may then be followed by a quiescent (unstimulated) time period of between about 2 hours and about 72 hours. Any appropriate stimulation intensity, duration, inter-stimulus frequency, and quiescent period may be used. Light intensity and low-frequency stimulation is particularly useful.

Implantable stimulator may be useful for appropriate stimulation of the vagus nerve to inhibit activation of granulocytes. In particular, non-contact stimulation devices may be useful. A non-contact stimulation device includes an output (e.g., an electrode or transducer) to stimulate the vagus nerve from some distance, such as outside of the nerve sheath. Since even light pressure (touch) to the vagus nerve may stimulate the vagus nerve as described herein, controlled stimulation may require the use of non-contact electrodes that do not apply pressure to the vagus nerve when the patient moves, for example.

Low-intensity or low levels of vagus stimulation may prevent desensitization of the inhibitory effect of vagus nerve stimulation. For example, traditional stimulation of the vagus nerve to drive cardiac pacing, to control seizures, to effect neuropsychological effects, and to treat gastrointestinal and eating disorders typically involves high-intensity and/or high frequency stimulation. Stimulation at these high levels is believed to overdrive the vagus nerve and may desensitize the ability of the granulocytes to respond to vagus stimulation. Desensitization or tachyphylaxis may prevent the sustained inhibition of granulocyte activation that is otherwise possible with the low level vagal stimulation described herein. For example, stimulating at an appropriate low level, may result in sustained inhibition of granulocyte activation for hours or days (e.g., 8 hours, 12, hours, 24 hours, 48 hours, etc.).

3. Applications

A stimulator may be configured to apply the low level of stimulation appropriate for inhibiting granulocyte activation. For example, an electrical stimulator may include one or more non-contact electrodes for placing near a subject's vagus nerve. In some variations, the non-contact electrode of the stimulator may be positioned near any region of the vagus nerve to inhibit granulocyte activation. For example, the electrode(s) may be transvascular electrodes that are placed subcalavicularly. In some variations, the electrodes are implanted behind a subject's ear or in other body regions. The entire stimulator may be implanted, or just the electrode(s) or transducer(s) may be implanted. For example, a mechanical stimulator may include a vibratory element (e.g., a piezoelectric transducer, a shape-memory element, etc.) that can apply pressure to the vagus nerve. The electrode or vibratory element may be connected (via wires or wirelessly) to the rest of the stimulator, which may include a power source and controller for controlling the application of the stimulus. The stimulator controller may be configured to apply the appropriate low-level of stimulation described above.

In some variations, the stimulator receives feedback from one or more sensors. In particular, sensors for determining the activation level of granulocytes may be useful to provide to help control stimulation. Thus, a method of inhibiting granulocyte activation or of treating a disease or disorder by inhibiting granulocyte activation may include a step of determining the activation level of the granulocytes. FIG. 3, described below, shows one variation of a method using such feedback.

Any appropriate sensor may be used. For example, a sensor may be specific to detecting presence or levels of one or more markers of granulocyte activation. In one example, a sensor determines the level of expression of a glycoprotein receptor on the surface of the granulocytes, such as CD11b.

A system for inhibiting activation of granulocytes may include a stimulator configured to apply the appropriate level of stimulation and a sensor configured to detect a level of granulocyte activation. For example, a system may include a sensor for sensing the level of CD11b on neutrophils in the subject's blood, and a stimulator configured to stimulate at the appropriate low-level to inhibit activation of neutrophils without desensitizing the response. In some variations, a system for inhibiting activation of granulocytes may also include a controller for receiving information from the sensor, analyze the sensed information, and provide feedback (including instructions) to the stimulator.

A sensor and stimulator may also be used to determine if a subject is responsive to stimulation of the vagus to prevent and/or treat a granulocyte-mediated disease or disorder. Individual subjects may respond differently to stimulation of their vagus nerve. The subject may be tested to determine if they are responsive to vagal stimulation to inhibit granulocyte activation, and would benefit from this treatment. Thus, we described herein methods and systems for determining if a subject is a good candidate for inhibition of granulocyte activation by vagal stimulation.

FIG. 1 illustrates one method of screening a subject to determine the subject's response to inhibition of granulocyte activation by vagal stimulation. In the first step 101, the subject's blood is sampled, and then a baseline granulocyte activation level 105 is determined. Optionally, the blood may be challenged with endotoxin 103 prior to determining the activation level. The subject's vagus nerve may then be stimulated 107 (per any of the stimulation methods and protocols described above.), and the blood is again sampled 109 and the activation level determined 113 (optionally, the blood sample may be challenged with endotoxin 111 first, as in step 103). A response level of granulocyte activation can be measured from this second sample. The first and second levels of granulocyte activation can be compared to determine the robustness of the effect (e.g., inhibition of granulocyte activation). In some variations, different markers may be tested, including markers such as CD11b that are typically responsive to vagal stimulation, as well as markers that are not typically responsive.

A system for determining the subject's responsiveness to vagal stimulation and inhibition of granulocyte activation may include stimulation analysis logic for receiving simulation sensor input and stimulation protocols. Thus, this system may include hardware, software or some combination thereof to receive and analyze the subject's granulocyte activation response. For example, a system may include a microcomputer or other processor, including memory, configured to receive and analyze sensor data and data to/from the stimulator. In some variations, the system includes an output (e.g., a monitor or telemetry) for presenting information (including the data) about the subject's response.

In one exemplary system (such as the system shown schematically in FIG. 2) a subject may be implanted with a vagus nerve stimulator, as described above. The vagus nerve stimulator may include a transducer (e.g., electrode, force applicator, etc.) for applying stimulation to the vagus nerve (either directly or indirectly). The transducer may be connected wirelessly or may be wired to the rest of the stimulation. The stimulator may also communicate with a stimulator controller that controls the application of stimulation. Communication between the stimulator and the controller may be wireless or wired. The controller may include a processor, and may also receive information from one or more sensors. The processor may include a memory, and either or both analysis logic (competent to analyze the sensor data) and stimulation logic (to help in controlling the stimulator).

A subject may also be screened to determine the level and/or frequency of stimulation to inhibit granulocyte activation without desensitizing the response of the granulocytes to vagal stimulation. FIG. 3 schematically illustrates a modification of the method of FIG. 1 that may be used to optimize stimulation applied to the vagus nerve to inhibit granulocyte activation without desensitizing. In FIG. 3, the vagus nerve is initially stimulated 107 as described above, and a response level for inhibition may be determined 113. After a predetermine period of time 315 the subject's blood can be sampled 317 and the activation level of granulocytes determined to see if they are still inhibited (or to what extent it is still inhibited) 321. Optionally, the blood sample may be challenged with endotoxin 319 as previously mentioned for steps 103 and 111. Challenging with endotoxin may magnify or otherwise help resolve the activation level of the granulocytes. If the inhibition of granulocytes has worn off, or if normal granulocyte activation has returned to some threshold level, the vagus nerve may be again stimulated, repeating the process. Any appropriate threshold (e.g., 50%, 70%, 80%, 90%, 100%) may be used. A system such as the system illustrated in FIG. 2 may be used to implement this method.

4. Example

Inhibition of CD11b Expression by Mechanical Stimulation of Vagus

FIGS. 4-7 illustrate the inhibition of granulocyte activation by stimulating the Auricular branch of a subject's vagus nerve. Surprisingly, robust inhibition of the granulocyte activation was seen after only very brief, low intensity stimulation of the subject's vagus nerve. Stimulation was indirect, mechanical stimulation applied externally.

In this example, level of granulocyte (e.g., neutrophil) activation was determined by assaying CD11b or CD16b level at differ times following stimulation. The stimulation applied was mechanical stimulation, consisting of a relatively soft vibration to the external cymba choncha of the subject's ear (right ear). Stimulation was applied for between one minute and five minutes (e.g., one minute in some tests and five minutes in other tests). The frequency of the vibration during the one minute period was between 200 Hz and 0.1 Hz (e.g., 10 Hz). Following the application of stimulation, the subject was not stimulated again. The neutrophil activation was assayed before activation, twenty minutes after activation, sixty minutes after activation and twenty-four hours after activation. Activation was assayed by immunoreactivity from sampled blood. For example, blood samples were put into Lithium heparin tubes. The vagus nerve was stimulated 15 min after baseline blood draw. The subject shown in FIGS. 4-7 was stimulated for one minute (vagus nerve stimulation or “VNS”).

At various times after stimulation (e.g., 20 min, 60 min, and 24 hr), blood was collected and sampled. Blood was kept at room temperature and stained for reactivity with anti-CD11b or CD16b antibody on day 2. Staining was performed by first mixing the blood with RPMI (gently). For each time point, 450 μl of blood was aliquoted into two separate FACS tubes (A and B). RPMI media (45 μl) was added to Tube A, and LPS (45 μl, 500 ng/ml, for a final 50 ng/ml) was added to Tube B. Thus, Tube B is the endotoxin-stimulated (or challenged) sample. The tubes are then incubated at 37 C in 5% CO₂ for 30 min, then placed on ice. For each sample, 100 μl of blood is aliquoted into FACS tubes containing 18 μl antibody (prepared and set on ice). Controls without antibody, and isotype controls were also performed.

After gently mixing the samples, they were incubated for 60 min at 4° C. (in the dark), and transferred to room temperature conditions where 2.5 ml RBC lysis solution was added, the cells vortexed, and let sit 5-6 min. After an addition vortexing, the cells were again allowed to sit 5-6 min (at room temp), and then centrifuged (1200 rpm for 5-7 min). Cells were then aspirated, washed with PBS (twice), and again aspirated and resuspended in 350 ul PBS, and fixed by adding fixative.

Samples were then ‘read’ using a flow cytometer (e.g., BD FacsCalibur™). Gating was on ‘neutrophils’ using FSC vs. SSC and CD16b+. Total mean fluorescence intensity (MFI) for each sample was measured, and background of isotype control was subtracted (if necessary).

The effect of VNS on total (neutrophil) CD11b expression in one subject is shown in FIGS. 4 and 5 in both the LPS unchallenged (FIG. 4) and challenged (FIG. 5) situations, respectively. In this subject there was very little difference in activation level of neutrophils twenty minutes after stimulation. Thus, the total mean florescence intensity (MFI) of immunolabeled CD11b twenty minutes after stimulation was approximately the same as the MFI of CD11b immediately prior to stimulation (clear bar). After one hour post-VNS, the activation level of the neutrophils, as reflected by the intensity of CD11b staining, begin to fall, an inhibition that was sustained over at least the first twenty-four hours post-VNS. In cells that were challenged with endotoxin (LPS-challenged), the same trend of activation was seen. As expected, the level of CD11b was greatly increased in LPS-challenged cells, as reflected by the CD11b total MFI.

FIGS. 6 and 7 show the percent reduction in neutrophil CD11b expression (and thus granulocyte activation) in one subject following VNS, compared to immediately before stimulation. Although this subject showed little inhibition shortly after VNS (e.g., at 20 min), a profound, long-lasting inhibition (e.g., beyond 24 hours) developed thereafter, without addition stimulation. From previous experimental data, it is known that overstimulating the Vagus nerve (including mechanically overstimulation), may reduce or eliminate this long-lasting inhibition of granulocyte activation.

While the methods and devices have been described in some detail here by way of illustration and example, such illustration and example is for purposes of clarity of understanding only. It will be readily apparent to those of ordinary skill in the art in light of the teachings herein that certain changes and modifications may be made thereto without departing from the spirit and scope of the invention.

Claims

1. A method of treating and/or preventing a granulocyte-mediated disease or disorder in a subject, the method comprising: detecting a granulocyte activation level; andstimulating the subject's inflammatory reflex in an amount sufficient to achieve an inhibition in expression of a marker of granulocyte activation without desensitizing the response of the subject's granulocytes to vagal stimulation.

2. The method of claim 1, further comprising stimulating the subject's inflammatory reflex to achieve a sustained reduction of expression of the marker of granulocyte activation.

3. The method of claim 1, further comprising stimulating the subject's inflammatory reflex to achieve a reduction of expression of the marker of granulocyte activation without substantially reducing the expression of CD16b.

4. The method of claim 1, wherein the marker of granulocyte activation is CD11b expression.

5. The method of claim 1, wherein the granulocytes affected by stimulation of the inflammatory reflex are neutrophils.

6. The method of claim 1, wherein the granulocyte-mediated disease or disorder granulocyte is selected from the group consisting of: diabetes, atherosclerosis, cancer, septic shock, acute respiratory distress syndrome (ARDS), bacterial meningitis, acute pancreatitis, multiple organ failure (MOF), post-ischemic reperfusion, acute cellulitis, abdominal aortic aneurysm, asthma, osteomyelitis, Crohn's disease, cystic fibrosis, emphysema, septic or bacterial pyelonephritis, rheumatoid arthritis, septic arthritis, uveitis, periodontitis, psoriasis, severe burns, skin ulceration, acute lung injury, pneumonia, trauma, severe early graft dysfunction, brochioeactasis, chronic obstructive pulmonary disease (COPD), complications with hemodialysis, hypersensitivity pneumonitis, lung fibrosis, herpes stromal keratitis, vascular restenosis, glomerulonephritis, hypersensitivity, cardiac rupture arising as a complication with myocardial infarction, multiple sclerosis, stroke or cerebral ischemia, and traumatic brain injury.

7. The method of claim 1, wherein the inflammatory reflex is stimulated by electrical stimulation.

8. The method of claim 1, wherein the inflammatory reflex is stimulated by mechanical stimulation.

9. The method of claim 1, wherein the inflammatory reflex is stimulated by electromagnetic stimulation.

10. The method of claim 1, wherein the stimulation comprises extremely low frequency, low level stimulation.

11. The method of claim 1, further comprising implanting a stimulator for stimulating the inflammatory reflex.

12. The method of claim 1, further comprising determining if the subject is a candidate for inhibition of granulocyte-mediated disease or disorder by stimulation of the inflammatory reflex.

13. The method of claim 1, wherein the step of stimulating the inflammatory reflex comprises stimulating the vagus nerve.

14. A method of treating and/or preventing a granulocyte-mediated disease or disorder in a subject, the method comprising: stimulating the subject's vagus nerve in an amount sufficient to inhibit the expression of CD11b on the surface of the subject's granulocyte cells without desensitizing the response of the granulocytes to vagal stimulation; andscreening the subject at different times to determine the extent of inhibition of granulocyte activation in response to vagal stimulation.

15. The method of claim 14, wherein the stimulation of the subject's vagus nerve is sufficient to inhibit CD11b expression for a period of greater than 12 hours.

16. The method of claim 14, wherein the disease or disorder is selected from the group consisting of: diabetes, atherosclerosis, cancer, septic shock, acute respiratory distress syndrome (ARDS), bacterial meningitis, acute pancreatitis, multiple organ failure (MOF), post-ischemic reperfusion, acute cellulitis, abdominal aortic aneurysm, asthma, osteomyelitis, Crohn's disease, cystic fibrosis, emphysema, septic or bacterial pyelonephritis, rheumatoid arthritis, septic arthritis, uveitis, periodontitis, psoriasis, severe burns, skin ulceration, acute lung injury, pneumonia, trauma, severe early graft dysfunction, brochioeactasis, chronic obstructive pulmonary disease (COPD), complications with hemodialysis, hypersensitivity pneumonitis, lung fibrosis, herpes stromal keratitis, vascular restenosis, glomerulonephritis, hypersensitivity, cardiac rupture arising as a complication with myocardial infarction, multiple sclerosis, stroke or cerebral ischemia, and traumatic brain injury.

17. The method of claim 14, wherein the stimulation is mechanical stimulation, electrical stimulation, or electromagnetic stimulation.

18. The method of claim 14, wherein the stimulation comprises pressure applied to the subject's vagus nerve.

19. The method of claim 14, wherein the stimulation comprises extremely low frequency, low level stimulation.

20. The method of claim 14, further comprising implanting a stimulator configured to apply stimulation to the subject's vagus nerve.

21. A method of treating and/or preventing a granulocyte-mediated disease or disorder in a subject, the method comprising: detecting a baseline granulocyte activation level; andapplying a first stimulation to the subject's inflammatory reflex to inhibit granulocyte activation in response to the detected granulocyte activation level.

22. The method of claim 21, wherein the step of applying stimulation to the subject's inflammatory reflex comprises stimulating the subject's vagus nerve.

23. The method of claim 21, further comprising: detecting a second granulocyte activation level after a predetermined time after applying the first stimulation to the subject's inflammatory reflex;comparing the second granulocyte activation level with the baseline granulocyte activation level to determine a level of inhibition; andapplying a second stimulation to the subject's inflammatory reflex when the level of inhibition exceeds a predetermined threshold.

24. The method of claim 21, wherein the step of detecting a granulocyte activation level comprises detecting expression of CD11b expression on granulocytes.

25. The method of claim 21, wherein the stimulation comprises mechanical stimulation.

26. The method of claim 21, wherein the stimulation comprises electrical stimulation.

27. The method of claim 21, wherein the stimulation comprises electromagnetic stimulation.